Portal de Periódicos da CAPES

Post-Void Residual Urine Volume is Not a Good Predictor of the Need for Invasive Therapy Among Patients With Benign Prostatic Hyperplasia

2005; Lippincott Williams & Wilkins; Volume: 175; Issue: 1 Linguagem: Inglês

10.1016/s0022-5347(05)00038-8

1527-3792

Chaidir Arif Mochtar, Lambertus A. Kiemeney, Melanie M. van Riemsdijk, M. Pilar Laguna, F.M.J. Debruyne, Jean de la Rosette,

Pelvic floor disorders treatments

No AccessJournal of UrologyAdult urology1 Jan 2006Post-Void Residual Urine Volume is Not a Good Predictor of the Need for Invasive Therapy Among Patients With Benign Prostatic Hyperplasia C.A. Mochtar, L.A.L.M. Kiemeney, M.M. van Riemsdijk, M.P. Laguna, F.M.J. Debruyne, and J.J.M.C.H. de la Rosette C.A. MochtarC.A. Mochtar Department of Urology, Academic Medical Centre, Amsterdam , L.A.L.M. KiemeneyL.A.L.M. Kiemeney Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen Department of Epidemiology, Radboud University Nijmegen Medical Centre, Nijmegen , M.M. van RiemsdijkM.M. van Riemsdijk GlaxoSmithKline Corporation, Zeist, the Netherlands , M.P. LagunaM.P. Laguna Department of Urology, Academic Medical Centre, Amsterdam , F.M.J. DebruyneF.M.J. Debruyne Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen , and J.J.M.C.H. de la RosetteJ.J.M.C.H. de la Rosette Department of Urology, Academic Medical Centre, Amsterdam View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)00038-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assessed the value of baseline PVR as predictor of the need for invasive therapy during long-term followup of patients with clinical BPH treated initially with α1-blockers or WW. Materials and Methods: The records of a cohort of 942 patients with BPH treated with α1-blockers or WW were reviewed. Baseline I-PSS scores, PSA, prostate volume, uroflowmetry, pressure flow parameters and followup data were collected prospectively. Correlations between PVR and other baseline parameters were calculated. The 5-year cumulative risks of invasive therapy were calculated with the Kaplan-Meier method. After stratification of PVR by various cutoff levels (50, 100 and 300 ml), rate ratios between large and small PVRs were calculated using proportional hazards analyses. Results: PVR has weak (-0.2<R <0.2) correlations with other baseline parameters. With increasing PVR cutoff levels, the 5-year cumulative risk of invasive therapy for the large PVR subgroup, increases from 45% to 64% and from 15% to 21% in the α1-blockers and WW group, respectively. Large PVR yields a significant 2-fold up to a 4-fold increased risk of invasive therapy compared to small PVR in both treatment groups. In multivariate models these significant risk differences largely disappear, although a statistically not significant higher risk remains for the large PVR (greater than 300 ml) patients. Conclusions: In general, baseline PVR has little prognostic value for the risk of BPH related invasive therapy in patients on α1-blocker and WW. Only patients with large PVR have a 2-fold increased risk of invasive therapy compared to patients with smaller PVR. References 1 : The urodynamic assessment of lower urinary tract symptoms. In: Benign Prostatic Hyperplasia. Edited by . Paris: Health Publication Ltd2001: 227. Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, June 25-28, 2000. Google Scholar 2 : EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol2001; 40: 256. Google Scholar 3 : AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol2003; 170: 530. Google Scholar 4 : Value of postvoid residual urine determination in evaluation of prostatism. Urology1982; 20: 602. Google Scholar 5 : Serial residual volumes in men with prostatic hypertrophy. Br J Urol1988; 62: 571. Google Scholar 6 : The day-to-day variation (test-retest reliability) of residual urine measurement. Br J Urol1996; 77: 192. Google Scholar 7 : Variability of post-void residual urine volume in the elderly. Urol Res1996; 24: 23. Google Scholar 8 : Distribution of post-void residual urine volume in randomly selected men. J Urol1999; 161: 122. Link, Google Scholar 9 : Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia pooled analysis of eleven controlled studies with alfuzosin. Urology2001; 57: 459. Google Scholar 10 : Benign prostatic hyperplasia: a progressive disease of aging men. Urology2003; 61: 267. Google Scholar 11 : Can transabdominal ultrasound estimation of postvoiding residual (PVR) replace catheterization?. Urology1988; 31: 445. Google Scholar 12 : Regression models and life tables. J Roy Stat Soc1972; 34: 187. Google Scholar 13 : Is the conservative management of chronic retention in men ever justified?. BJU Int2003; 92: 581. Google Scholar 14 : Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. Eur Urol2000; 37: 528. Google Scholar 15 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2387. Google Scholar 16 : Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol2002; 42: 1. Google Scholar 17 : Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. Urology2000; 56: 610. Google Scholar 18 : Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol2000; 163: 13. Link, Google Scholar 19 : Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology1999; 53: 473. Google Scholar 20 : Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology1996; 48: 398. Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byMeeks J, Erickson B, Granieri M and Gonzalez C (2009) Stricture Recurrence After Urethroplasty: A Systematic ReviewJournal of Urology, VOL. 182, NO. 4, (1266-1270), Online publication date: 1-Oct-2009.Kaplan S, Wein A, Staskin D, Roehrborn C and Steers W (2008) Urinary Retention and Post-Void Residual Urine in Men: Separating Truth From TraditionJournal of Urology, VOL. 180, NO. 1, (47-54), Online publication date: 1-Jul-2008. Volume 175Issue 1January 2006Page: 213-216 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordstreatment outcomeprostatic hyperplasiaadrenergic alpha-antagonistsMetricsAuthor Information C.A. Mochtar Department of Urology, Academic Medical Centre, Amsterdam Nothing to disclose. More articles by this author L.A.L.M. Kiemeney Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen Department of Epidemiology, Radboud University Nijmegen Medical Centre, Nijmegen Nothing to disclose. More articles by this author M.M. van Riemsdijk GlaxoSmithKline Corporation, Zeist, the Netherlands Financial interest and/or other relationship with GlaxoSmithKline and Sanofi-Aventis. More articles by this author M.P. Laguna Department of Urology, Academic Medical Centre, Amsterdam Nothing to disclose. More articles by this author F.M.J. Debruyne Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen Financial interest and/or other relationship with Zentaris. More articles by this author J.J.M.C.H. de la Rosette Department of Urology, Academic Medical Centre, Amsterdam Financial interest and/or other relationship with BSC, AMS and GSK. More articles by this author Expand All Advertisement PDF downloadLoading ...